

Table 2: Distribution of initial treatment regimens among the 679 treated patients who initiated treatment during follow-up).

	n (%)
IFNa monotherapy	248 (36.5)
NA	360 (53.0)
LAM alone	228 (63.3)
Adefovir Alone	10 (2.8)
Entecavir Alone	58 (16.1)
Tenofovir Alone	36 (10.0)
Tebivudine Alone	13 (3.6)
Tenofovir/Tebivudine	1 (0.3)
LAM/Adefovir	13 (3.6)
LAM/Tenofovir	2 (0.3)
IFNa+NA	71 (10.5)
IFNa+LAM	68 (95.8)
IFNa+LAM/Adefovir	1 (1.4)
IFNa+Adefovir	2 (2.8)

INFa: interferon, NA: nucleos(t)ide analogs, LAM: lamivudine